The United States has shifted its stance on Venezuela’s efforts in combating drug trafficking, removing the nation from its list of countries failing to meet international counternarcotics commitments. This development is a significant indicator of progress under interim President Delcy Rodríguez’s administration, potentially altering the dynamics of U.S.-Venezuelan relations in the fight against illicit drugs.
Previously, Venezuela had been consistently categorized as a country not fulfilling its counternarcotics obligations. However, the Trump administration has acknowledged improvements in Venezuela’s efforts to tackle drug-trafficking organizations. This decision marks a departure from past assessments and suggests a growing recognition of Venezuela’s counter-drug measures.
Colombia, however, remains on the U.S. list of countries not making substantial efforts against drug trafficking, reflecting ongoing concerns about its counternarcotics strategy. Despite being a key partner in the region, Colombia has been identified by the White House as one of four countries that have not sufficiently met international counternarcotics obligations over the past year. The U.S. government’s decision underscores the need for further action in Colombia to curb coca cultivation, cocaine production, and trafficking networks.
President Donald Trump has indicated that Colombia could potentially be removed from this list in the future, contingent upon demonstrating significant progress in combating drug-related challenges. Colombian officials have expressed their commitment to addressing the entire drug-trafficking chain, which includes efforts to dismantle production facilities, trafficking routes, and financial networks of criminal organizations.
These developments highlight Washington’s ongoing emphasis on counternarcotics collaboration with Latin American countries. While both Venezuela and Colombia are still identified as major drug-transit or illicit drug-producing nations, the U.S.’s revised classification of Venezuela signals a nuanced approach to its international drug policy and cooperation in the region.